Archives of “June 28, 2020” day

rss

Vaccine & Treatment Medical News:

  
Analysis, LINKS

Inside the Coronavirus (Scientific American)
• Why tech didn’t save us from covid-19 (MIT)
• The New Weapon in the Covid-19 War (Bloomberg)
• Study suggests 80% of Covid-19 cases in the US went undetected in March (CNN)
• Chinese Covid-19 Vaccines Cleared for Final Testing in UAE (Bloomberg)
• Can Covid Damage the Brain? (New York Times)
• What We Know—and Really Don’t Know—About the Future of COVID-19 Vaccines (Slate)
• Gilead is about to start trials of an inhaled version of Remdesivir (Gilead)
• How A Scientific Paper About A Promising COVID-19 Treatment Was Debunked (FiveThirtyEight) 

China PMIs due this coming week – the inside word preview

  
Analysis, Economy

Later in the week, Wednesday and Friday, are the private survey PMIs, Caixin/Markit.
Markit give a brief preview:
  • China’s PMIs will be especially closely watched given its earlier relaxation of virus-related restrictions. 
  • So far the data have shown encouraging strength, with business activity across manufacturing and services growing in May at the fastest rate since the start of 2011. 
  • The data for China may therefore help gauge the extent to which early rebounds in activity from lockdowns might fade. 
 I’ll have more on the Caixin/Markit PMIs on approach.
—
Official PMIs, manufacturing and non-manufacturing are due on Tuesday June 30 at 0100GMT
Manufacturing

  • expected 50.4, prior 50.6

Non-manufacturing

  • expected 53.5, prior 53.6

Composite

  • prior 53.4

China data – May 2020 industrial profits +6.0% y/y (prior -4.3%)

  
  Analysis

China’s industrial profits fell in Q1 and started to be not so bad through March and April as the economy crawled toward recovery.

  • May comes in at +6.0% y/y from -4.3% in April
  • For January to May (ie. YTD) still down, coming in at -19.3% y/y
Industrial profits are important, they give firms a base from which to build on for investment (capex) ahead.
Virus impacts and its impact on demand both domestically and offshore are obviously the main suspect for China data impacts, but mix in factory gate price deflation (reflected in persistent negative PPIs) also. Profits declined 3.3% in 2019, so were weak even heading into 2020.

Japan press says Japan to ready 1m doses of coronavirus vaccine for swift distribution. Note, there is no vaccine.

  
  Analysis

Nikkei with the report that biotech venture AnGes will ready production capacity for 1 million doses of COVID19 vaccines by March

They also say, and this is key (!): AnGes-led team ramps up capacity while product is still under development
So, yeah, there is no vaccine, but if there was we’d be ready to ship it! In 9 months.
A bit of weekend pump for ya’all.
Here’s the Nikkei link (may be gated)
Go to top